Brucella antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Brucella antibodies pairs and antigen for animal health (animal Dog/Canine, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease Brucellosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P248-Tg001-Ag01	Recombinant Brucella protein	$3090.00
GMP-VT-P248-Tg001-Ab01	Anti-Brucella mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P248-Tg001-Ab02	Anti-Brucella mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P248-Tg001-Ab03	Anti-Brucella human monoclonal antibody (mAb)	$3090.00
GMP-VT-P248-Tg001-Ab04	Anti-Brucella human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P248-Tg001-Ag01
Product Name	Recombinant Brucella protein
Pathogen	Brucella
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Brucella antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Brucella level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease with Brucellosis.
Tag	His
Product description	Recombinant Brucella proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P248-Tg001-Ab01,GMP-VT-P248-Tg001-Ab02
Pathogen	Brucella
Product Name	Anti-Brucella mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Brucella antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella antibodies in Brucella level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease with Brucellosis.
Product description	Anti-Brucella mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P248-Tg001-Ab03,GMP-VT-P248-Tg001-Ab04
Pathogen	Brucella
Product Name	Anti-Brucella human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Brucella antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella antibodies in Brucella level test of animal Dog/Canine, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease with Brucellosis.
Product description	Anti-Brucella mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Candida albicans: A Comprehensive Scientific Exploration

Introduction:

Candida albicans, an opportunistic fungal pathogen, occupies a pivotal position in microbiological research due to its relevance in human health and disease. This article aims to provide an in-depth scientific examination of Candida albicans, spanning taxonomy, structural features, pathogenicity, host-pathogen interactions, associated diseases, and diagnostic methodologies. By presenting this multifaceted exploration, we aim to offer a comprehensive and authoritative resource, enhancing its visibility in Google search results for the benefit of researchers, healthcare professionals, and curious individuals seeking a profound understanding of this yeast species.

1. Taxonomy and Classification:

The taxonomy of Candida albicans is intricate and warrants detailed scrutiny. Classified within the kingdom Fungi, phylum Ascomycota, and the class Saccharomycetes, it belongs to the Candida genus at the family level. The species designation is Candida albicans. This precise taxonomic placement is crucial for elucidating evolutionary relationships and understanding the genetic makeup of this organism.

2. Structural Features:

A deeper understanding of Candida albicans requires an exploration of its structural features, which significantly influence its pathogenicity. The intricate examination includes:

Cell Wall Composition: The cell wall of Candida albicans is a dynamic structure comprising glucans, mannans, and proteins. This section delves into the complexities of cell wall architecture, emphasizing its role in interactions with the host immune system.

Morphological Transitions: Candida albicans displays a remarkable ability to transition between yeast and hyphal forms. This morphological plasticity is a key determinant of its pathogenicity, influencing tissue invasion and immune evasion.

Virulence Factors: The arsenal of virulence factors possessed by Candida albicans contributes to its pathogenic potential. A detailed discussion of factors such as secreted aspartyl proteases (SAPs) and phospholipases sheds light on their functions and implications in the context of infection.

3. Host-Pathogen Interactions and Associated Diseases:

Understanding the intricate interplay between Candida albicans and its host is crucial for unraveling the spectrum of diseases associated with this organism. This section addresses:

Host Range: While Candida albicans primarily targets humans, it can also infect other mammals, underscoring its adaptability.

Disease Spectrum: The diseases attributed to Candida albicans range from superficial mucosal infections like oral thrush to invasive candidiasis with life-threatening consequences. The nuanced exploration of these diseases provides a comprehensive overview.

Immunocompromised Hosts: Immunocompromised individuals are particularly susceptible to Candida albicans infections. This section elucidates the heightened risks and clinical implications, emphasizing the importance of tailored therapeutic approaches.

4. Diagnostic Approaches:

Accurate and timely diagnosis is paramount in managing Candida albicans infections. This section provides a meticulous overview of various diagnostic methodologies:

Microscopy: High-resolution microscopy techniques enable the visualization of yeast cells and hyphal structures, aiding in rapid diagnosis.

Culture-Based Methods: The traditional yet essential approach of culturing Candida albicans provides valuable insights into its growth characteristics and susceptibility patterns.

Molecular Techniques: Nucleic acid-based methods, including polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), offer precise identification, facilitating targeted therapeutic interventions.

Immunoassays: Enzyme immunoassays and serological tests play a pivotal role in detecting Candida antigens and antibodies, contributing to a comprehensive diagnostic profile.

Emerging Technologies: Acknowledging the dynamic nature of diagnostic technologies, this section explores cutting-edge approaches that may have emerged post the last update, offering a glimpse into the evolving landscape of Candida albicans diagnostics.

In conclusion, this detailed scientific exploration of Candida albicans aims to serve as an authoritative resource, contributing to the understanding of this versatile fungal pathogen. By weaving together taxonomic insights, structural intricacies, pathogenic mechanisms, host interactions, associated diseases, and diagnostic methodologies, we endeavor to provide a comprehensive overview that meets the information needs of diverse audiences. The meticulous detailing in each section not only enriches the scientific discourse surrounding Candida albicans but also enhances the search engine visibility of this resource, ensuring its accessibility to those seeking profound insights into this intriguing fungal species.

About GDU